Name:	chrs_AccruedMilestonePayment
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Represents co-development, regulatory and technology transfer costs.

No definition available.

Name:	chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Amount of additional clinical milestones eligible to receive

No definition available.

Name:	chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Maximum aggregate milestone payments to be made

No definition available.

Name:	chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds

No definition available.

Name:	chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement.

No definition available.

Name:	chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Amount of milestone payments earned

No definition available.

Name:	chrs_CollaborationAgreementMilestonePaymentsEarned
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Number of undisclosed preclinical immuno-oncology drug candidates under the collaboration agreement.

No definition available.

Name:	chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates
Namespace Prefix:	chrs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The amount of option exercise fee per program under the collaboration agreement.

No definition available.

Name:	chrs_CollaborationAgreementOptionExerciseFeePerProgram
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Represents the percentage of royalty on net sales under the collaboration agreement.

No definition available.

Name:	chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

Represents the percentage of royalty on net sales for each option program under the collaboration agreement.

No definition available.

Name:	chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

Period for payment of nominal research maintenance fee

No definition available.

Name:	chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee
Namespace Prefix:	chrs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Amount of regulatory milestones eligible to receive

No definition available.

Name:	chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Technical milestone payments obligated to pay

No definition available.

Name:	chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Term of agreement

No definition available.

Name:	chrs_CollaborationAgreementTerm
Namespace Prefix:	chrs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement.

No definition available.

Name:	chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Represents costs associated to a collaboration agreement.

No definition available.

Name:	chrs_CollaborationCosts
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Amount of decrease in research and development expenses for release of certain liabilities.

No definition available.

Name:	chrs_DecreaseInResearchAndDevelopmentExpensesForReleaseOfCertainLiabilities
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Represents the maximum paid amount for co-development activities.

No definition available.

Name:	chrs_MaximumAmountPaidCoDevelopmentActivities
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Maximum antibodies partially exercised under commercialization option

No definition available.

Name:	chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption
Namespace Prefix:	chrs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Maximum number of antibodies under for research option

No definition available.

Name:	chrs_MaximumNumberOfAntibodiesUnderForResearchOption
Namespace Prefix:	chrs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Amount per each installment of milestone payments under collaborative arrangements.

No definition available.

Name:	chrs_MilestonePaymentsAmountPerEachInstallment
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Minimum antibodies to be commercialized under commercialization option

No definition available.

Name:	chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption
Namespace Prefix:	chrs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Minimum Number of Antibodies under Commercialization option

No definition available.

Name:	chrs_MinimumNumberOfAntibodiesUnderCommercializationOption
Namespace Prefix:	chrs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Percentage of option fee to be paid on partial exercise of commercialization option

No definition available.

Name:	chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

Amount of potential development milestones entitled.

No definition available.

Name:	chrs_PotentialDevelopmentMilestonesEntitled
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Amount of regulatory milestones eligible to pay.

No definition available.

Name:	chrs_RegulatoryMilestonesEligibleToPay
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Amount of sales milestones entitled.

No definition available.

Name:	chrs_SalesMilestonesEntitled
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1

Name:	us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Price of a single share of a number of saleable stocks of a company.

No definition available.

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

Name:	us-gaap_TypeOfArrangementAxis=chrs_VaccinexLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=chrs_ExclusiveLicenseAndCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=chrs_AntiTigitAntibodyAndIl2CytokineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=chrs_AdimabDevelopmentAndOptionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=chrs_NovartisAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=chrs_GskAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	dei_LegalEntityAxis=chrs_SurfaceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_BalanceSheetLocationAxis=chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: